Literature DB >> 21507920

Strategies for reduction in duration of antibiotic use in hospitalized patients.

Yoshiro Hayashi1, David L Paterson.   

Abstract

There is a global crisis of antibiotic resistance in part because of the collateral damage of antibiotic use. Reduction in antibiotic consumption is clearly important to minimize this problem. Limiting treatment duration may be the most clinically palatable means of reducing antibiotic consumption. Antimicrobial stewardship programs play an important role in this process. Their effectiveness may be increased by drawing on evidence from randomized controlled trials regarding optimal antibiotic duration. However, in most clinical scenarios, the recommended duration of therapy in published guidelines is based on expert opinion. Biological markers, such as procalcitonin, have been shown to reduce antimicrobial consumption with no adverse outcome in 11 randomized controlled trials. Although procalcitonin may not be the perfect biomarker, the concept of procalcitonin-guided antibiotic discontinuation after clinical stabilization, in conjunction with antimicrobial stewardship programs, appears to be ready for introduction into clinical practice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21507920     DOI: 10.1093/cid/cir063

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  34 in total

Review 1.  An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients.

Authors:  Dimitrios K Matthaiou; Georgia Ntani; Marina Kontogiorgi; Garyfallia Poulakou; Apostolos Armaganidis; George Dimopoulos
Journal:  Intensive Care Med       Date:  2012-04-27       Impact factor: 17.440

2.  Procalcitonin for antibiotic treatment in intensive care unit patients.

Authors:  Nathalie Layios; Bernard Lambermont
Journal:  Curr Infect Dis Rep       Date:  2013-10       Impact factor: 3.725

3.  The Japanese guidelines for the management of sepsis.

Authors:  Shigeto Oda; Mayuki Aibiki; Toshiaki Ikeda; Hitoshi Imaizumi; Shigeatsu Endo; Ryoichi Ochiai; Joji Kotani; Nobuaki Shime; Osamu Nishida; Takayuki Noguchi; Naoyuki Matsuda; Hiroyuki Hirasawa
Journal:  J Intensive Care       Date:  2014-10-28

4.  Antimicrobial stewardship as part of the infection prevention effort.

Authors:  Rebekah W Moehring; Deverick J Anderson
Journal:  Curr Infect Dis Rep       Date:  2012-12       Impact factor: 3.725

5.  Unsolicited post-prescription antibiotic review in surgical and medical wards: factors associated with counselling and physicians' compliance.

Authors:  P Lesprit; C Landelle; C Brun-Buisson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-24       Impact factor: 3.267

6.  Antibiotic consumption after implementation of a procalcitonin-guided antimicrobial stewardship programme in surgical patients admitted to an intensive care unit: a retrospective before-and-after analysis.

Authors:  A Hohn; B Heising; S Hertel; G Baumgarten; M Hochreiter; S Schroeder
Journal:  Infection       Date:  2015-01-15       Impact factor: 3.553

7.  Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

Authors:  K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern
Journal:  Infection       Date:  2016-06       Impact factor: 3.553

Review 8.  Methodology in improving antibiotic implementation policies.

Authors:  Onur Özgenç
Journal:  World J Methodol       Date:  2016-06-26

Review 9.  Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.

Authors:  Xiao Jun Wang; Alexandre Chan
Journal:  Curr Oncol Rep       Date:  2017-03       Impact factor: 5.075

10.  Optimizing the Use of Antibacterial Agents in the Neonatal Period.

Authors:  Joseph B Cantey
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.